Page last updated: 2024-08-21

dihydroergotamine and sorafenib

dihydroergotamine has been researched along with sorafenib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, A; Chen, L; Dai, X; He, M; Li, S; Lian, J; Liao, Q; Liu, D; Shan, M; Sun, L; Xiang, L; Yang, M; Zhai, L; Zhang, Y1

Reviews

1 review(s) available for dihydroergotamine and sorafenib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for dihydroergotamine and sorafenib

ArticleYear
Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells.
    Biochemical pharmacology, 2023, Volume: 211

    Topics: Apoptosis; Cell Line, Tumor; Dihydroergotamine; Humans; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Sorafenib

2023